Amneal Pharmaceuticals
AMRX
241 hedge funds and large institutions have $1.16B invested in Amneal Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 105 increasing their positions, 59 reducing their positions, and 29 closing their positions.
221% more call options, than puts
Call options by funds: $1.78M | Put options by funds: $556K
78% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 59
17% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 29
2.24% more ownership
Funds ownership: 43.33% → 45.57% (+2.2%)
2% more funds holding
Funds holding: 237 → 241 (+4)
2% more capital invested
Capital invested by funds: $1.14B → $1.16B (+$17.6M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$22.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.5M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$11.5M |
| 4 |
Goldman Sachs
New York
|
+$9.79M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$7.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$14.1M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$12.6M |
| 3 |
HAI
Hennessy Advisors Inc
Novato,
California
|
-$12.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$8.28M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$5.73M |
AMRX Hedge Fund Activity: Q2 2025 in Review
241 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q2 2025, worth a combined $1.16B — up 1.5% from $1.14B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new AMRX positions and 29 closed out — a net gain of 5 holders — while 105 added to existing stakes and 59 trimmed.
The largest buyer was Millennium Management, adding an estimated $22.3M. The largest seller was Citadel Advisors, cutting an estimated $14.1M.
- 241 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q2 2025, up from 237 in Q1 2025.
- Funds reported $1.16B of Amneal Pharmaceuticals stock for Q2 2025, up 1.5% quarter-over-quarter.
- 34 funds opened new Amneal Pharmaceuticals positions in Q2 2025 and 29 closed out, a net change of +5 holders.
- The largest Amneal Pharmaceuticals buyer in Q2 2025 was Millennium Management, an estimated $22.3M added.
- The largest Amneal Pharmaceuticals seller in Q2 2025 was Citadel Advisors, an estimated $14.1M sold.
Based on aggregated 13F filings for Q2 2025.